)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
aXichem
aXichem (AXIC) investor relations material
aXichem Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Net sales for Jan–June 2026 were SEK 7,856 thousand, down from SEK 10,035 thousand year-over-year.
Operating loss improved to SEK -7,112 thousand from SEK -9,274 thousand year-over-year, mainly due to reduced regulatory costs.
Significant regulatory milestone achieved with EFSA's positive opinion on phenylcapsaicin as a salmonella-inhibiting additive in chicken feed.
Commercial launch of aXiphenⓇ ruminant in Brazil, with initial deliveries and new orders secured.
Financial highlights
Q2 2026 net sales were SEK 4,030 thousand, compared to SEK 6,648 thousand in Q2 2025.
Profit after tax for Jan–June 2026 was SEK -7,168 thousand, an improvement from SEK -9,289 thousand year-over-year.
Cash and cash equivalents at June 30, 2026, were SEK 2,873 thousand, down from SEK 6,781 thousand a year earlier.
Equity ratio increased to 93% from 90% year-over-year.
Earnings per share for Jan–June 2026 were SEK -0.11, compared to SEK -0.16 year-over-year.
Outlook and guidance
Anticipates final EU Commission approval for phenylcapsaicin as a feed additive by end of 2026.
Expects gradually increasing order intake in both animal feed and dietary supplements in coming years.
Focus remains on commercialization in Brazil, EU, and continued expansion in the US.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from aXichem
- Net sales rose 374% year-over-year, with improved losses and a strengthened, debt-free balance sheet.AXIC
Q4 2024 - Improved operating results and successful capital raising support growth in key markets.AXICQ1 2026
- Record sales growth and regulatory milestones set the stage for further expansion in 2026.AXICQ4 2025
- Sales surged and losses narrowed as demand for aXiviteⓇ and aXiphenⓇ accelerated.AXICQ3 2025
- Sales up 50% year-over-year, with key regulatory and commercial advances in core markets.AXICQ2 2025
- Strong sales growth and new capital support aXichem's continued commercialization and expansion.AXICQ3 2024
- Record sales growth and narrowed losses as aXivite and aXiphen gain market traction.AXICQ2 2024
- Strong sales growth and major orders offset by higher operating losses and regulatory costs.AXICQ1 2025
Next aXichem earnings date
Q3 202626 Nov, 2026
aXichem
Next aXichem earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
aXichem AB is a Swedish biotechnology company focused on developing natural analogue ingredients. Its flagship product, phenylcapsaicin, is a synthetic version of capsaicin used in various industries, including animal feed, dietary supplements, and marine applications. The company's solutions include aXivite, which is used in health supplements to support weight management and gut health, and aXiphen, a bio-repellent applied in agriculture, marine antifouling, and animal feed to promote health and prevent issues like salmonella in poultry. The company is headquartered in Malmö, Sweden, and its shares are listed on the Stockholm Stock Exchange.